◼ Archived
World
🔮 fades ✓
Roche’s changing plans show how MFN is complicating European drug launches
6 news sources are covering this World story right now — Archynetys is tracking how fast it spreads.
Roche
17 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Roche
This hub groups 17 separate news trends connected to Roche, spanning July 2, 2026 through October 27, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 131 article observations and 127 source signals, led by Business, Health, World coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Business
🔮 fades ✓
Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
Roche lung cancer drug extends survival by nearly six months in late-stage trial
◼ Archived
Business
🔮 fades ✓
Roche builds blockbuster BTK case for fenebrutinib in multiple sclerosis as FDA decision approaches
Roche’s MS pill slashes relapses by 55%, fueling a blockbuster BTK bid as an FDA decision looms.
◼ Archived
Business
🔮 fades ✓
Roche returns to China’s Hansoh for $15B biobucks ADC pact
8 news sources are covering this Business story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Roche Licenses Obesity Therapy From China’s Rona in Up to $1.2 Billion Deal
Roche licenses obesity therapy from China's Rona in major deal
◼ Archived
Business
🔮 fades ✓
Genentech pays Alector $100M for preclinical Parkinson’s prospect
Genentech’s $100 million upfront for Alector’s preclinical Parkinson’s candidate ignites a multi‑billion licensing race.
◼ Archived
Business
🔮 fades ✓
Roche Halts Development of Obesity Drug Candidate
Roche’s sudden halt of its muscle‑sparing obesity antibody reverberates through patients, investors and the biotech pipeline.
◼ Archived
Business
🔮 fades ✓
Roche Drug Candidate Hits Target in Late-Stage Study for Autoimmune Disease
Roche's Sefaxersen hits target in late-stage study for autoimmune disease
◼ Archived
Business
🔮 fades ✓
Roche Says Drug Helped Patients Reduce Blood-Sugar Levels, Weight in Trial
Roche's obesity drug shows promise in mid-stage trial with significant weight loss and improved blood sugar control.
◼ Archived
Health
🔮 fades ✓
Alzheimer’s trial to test drug on people without symptoms to see if it can be prevented
Roche’s experimental Alzheimer’s drug moves into a world‑first prevention trial, putting patients and health systems on a potential path to stop the disease before it starts.
◼ Archived
Business
🔮 fades ✓
Novartis Just Broke Out, Again, As Its Roche Rivalry Heats Up
Two positive Phase III results for an oral multiple sclerosis drug have pushed Novartis forward in a competitive pharmaceutical market.
◼ Archived
Business
🔮 fades ✓
Roche inks $1.53B deal for Simcere’s B-cell-targeting antibody
Roche’s $1.5 billion Asian deal promises new blood‑cancer therapy, yet hinges on a modest $75 million upfront.
◼ Archived
Business
BioNTech-Genentech cancer vax records more deaths than control in scrapped ph. 2 test
BioNTech and Roche have halted a mid-stage cancer vaccine trial after more deaths occurred in the treatment group than in the control group.
◼ Archived
Business
🔮 fades ✓
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
Roche’s $2.5 billion pact for Hanmi’s muscle‑sparing obesity drug ignites expectations for a new weight‑loss breakthrough
◼ Archived
Business
🔮 fades ✓
FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly
The FDA has granted clearance for the first blood-based biomarker test for Alzheimer's disease, developed through a partnership between Roche and Eli Lilly.
◼ Archived
Health
🔮 fades ✗
New Alzheimer’s drug could stop disease
A new generation of Alzheimer’s drug treatments has entered the spotlight, promising potential to halt the disease before symptoms manifest.
◼ Archived
Business
🔮 fades ✓
Roche Lung-Cancer Drug Candidate Beats Existing Therapies in Late-Stage Trial
Roche's KRAS G12C inhibitor, divarasib, outperformed rival therapies in a head-to-head Phase 3 trial for lung cancer.